Introduction
Multiple sclerosis (MS) is a chronic autoimmune disease of the central nervous system (CNS) . It is the main cause of non-traumatic neurological disability in young adults. MS mostly affects people aged 20-50 years, although it can occur in young children and much older adults. An estimated 2.5 million people in the world have MS and it is at least 2-3 times more common in women than in men. Other factors identified in the distribution of MS include age, genetics, environment, and ethnic background (Olsson et al., 2017) . It is likely lifestyle factors that have changed over time and people tending to live longer with MS will have affected the rates of prevalence and incidence of MS (Multiple Sclerosis Trust, 2018; National MS Society, 2018) .
MS is usually associated with progressive degrees of disability, in which chronic inflammation gives rise to multifocal demyelination of axons in both white and gray matter of the CNS (Kutzelnigg and Lassmann, 2014) . The disease involves axonal degeneration and causes brain and spinal cord neuronal loss and atrophy (Geurts et al., 2012) . Diagnosis of MS commonly involves finding lesions (plaques) in at least two separate areas of the CNS, including the brain, spinal cord, and optic nerves (Paul et al., 2019) . However, diagnosing MS is often difficult and is based on a patient's medical history including symptoms, phys-procedure, requires a clinical specialist to perform it, and can lead to adverse effects. It is likely the emergence of accurate and reliable CSF biomarkers, together with the development of safe and effective intrathecal therapies, will result in CSF analysis becoming a routine part of optimal MS clinical management (Harris et al., 2017) . Collections of peripheral blood are less invasive and more easily obtained than collections of CSF. Blood-derived biomarkers able to detect disease activity in MS and distinguish the different disease phenotypes may be advantageous in personalized MS treatment with disease-modifying drugs and to predict response to treatment.
MicroRNAs (miRNAs) are small, single-stranded, non-coding RNAs that repress the expression of target genes via post-transcriptional mechanisms by binding to complementary sequences in the 3′ or 5′ UTR (untranslated) region of the target messenger RNA (Lytle et al., 2007) . However, more recently it has been shown that miRNAs may mediate both activation and inhibition of transcription of a target gene (Catalanotto et al., 2016) . The remarkable stability of miRNAs in body fluids, together with sensitive methods for their detection and quantitation, has led to circulating miRNAs being investigated as biomarkers for various human diseases and disorders (Peplow et al., 2019) , including neurodegenerative diseases and other neurologic pathologies (Sheinerman and Umansky, 2013) . Increasing evidence has revealed an altered pattern of expression of miRNAs in autoimmune diseases. Further understanding of miRNA dysregulation and its mechanisms during the development of different autoimmune diseases has enormous potential to develop novel therapeutic targets or strategies, as well as identifying novel circulating or exosomal miRNA biomarkers (Long et al., 2018) . Exosomes are membrane bound vesicles shed by almost all cell types and contain, amongst others, miR-NAs. A significant increase in circulating exosome concentration occurs in many inflammatory diseases (Momen-Heravi et al., 2015; Lee et al., 2016) . As exosomes can cross the bloodbrain barrier, some of the circulating exosomes in MS patients may be derived from affected CNS cells or the associated inflammatory environment (Pusic et al., 2014) .
In a review on miRNAs, Fawaz et al. (2015) wrote "Recently, recognizing the importance of biofluid biomarkers for enhancing our understanding of MS, it has been discussed their inclusion in the McDonald diagnostic criteria improves the sensitivity and specificity of diagnosis. However, the insufficient evidence of a reliable link between MS clinical course and biological markers, as well as considerable population and interlaboratory variability, and a lack of standardized procedures did not allow their inclusion at this time. Further advances in technology, development of sensitive biomarker assays and clinical validation studies are necessary". The review listed dysregulated miRNAs in MS patients reported in research articles published in the years 2009-2013; however, for many of the miRNAs the type of samples assayed (blood, serum, plasma, specific cell types) was not indicated. We have performed a PubMed search of articles on miRNAs in blood and CSF of MS patients published in the period January 2016-December 2018 to determine to what extent they confirm and extend the findings on dysregulated miRNAs in MS, are able to distinguish between the different MS phenotypes, and meet some of the concerns expressed by Fawaz et al. (2015) .
Clinical Phenotypes of Multiple Sclerosis
A first neurological event suggestive of MS usually experienced by patients is known as clinically isolated syndrome (CIS). It lasts for > 24 hours, with symptoms and signs indicating either a single lesion (monofocal) or several lesions (multifocal) within the CNS (Kappos et al., 2006) . On experiencing CIS a person may or may not develop MS, with the likelihood being greater in someone who has lesions on a MRI scan similar to those seen in MS (National MS Society, 2018) .
Three clinical phenotypes of MS have been recognized (Lublin and Reingold, 1996; Bayer US, 2018; National MS Society, 2018) and serve for disease staging in the progression of MS. They are: 1) Relapsing-remitting MS (RRMS): About 85% of people with adult-onset MS are initially diagnosed with this condition. Individuals with RRMS have clearly defined relapses (also called attacks or exacerbations), lasting from days to weeks and then subsiding, with full or partial recovery and no apparent disease progression between attacks. True attacks must last over 24 hours, with the interval between attacks lasting at least 30 days (Kacperska et al., 2015) . The relapses are caused by reactive autoimmune cells, which cause focal inflammation and demyelination often seen on MRI. As inflammation decreases and remyelination occurs, relapses are followed by periods of clinical remission. In a recent study, 52% of patients with CIS developed RRMS within a 1-year study period (Ahlbrecht et al., 2016) .
2) Secondary-progressive MS (SPMS): After 10-20 years of disease, > 50% of RRMS patients will transition to SPMS, characterized by relapses without any recovery. Chronic inflammation with scar formation (sclerosis), increasing axonal damage and brain atrophy, and inhibition of remyelination occurring over time cause the progressive worsening of disabilities.
3) Primary-progressive MS (PPMS): In this phenotype of MS, the disease is progressive from clinical onset and occurs in ~15% of people with MS. It is characterized by slowly worsening symptoms from the beginning, without a preceding relapsing-remitting phase. It is clinically indistinguishable from SPMS.
Early-onset, juvenile or pediatric MS is defined as MS with an onset before the age of 16 years; 3-10% of MS patients present under 16 years of age and < 1% under 10 years of age (Boiko et al., 2002) . The disease course in pediatric MS is different to that in adults, with 98% of pediatric MS patients presenting with a RRMS course, and less likely to develop PPMS or SPMS in childhood (Renoux et al., 2007; Alroughani and Boyko, 2018) . Furthermore, the relapse rate is higher than in adult-onset MS (Benson et al., 2014) .
MicroRNAs in Multiple Sclerosis and Disease Progression
Dysregulated expression of miRNAs associated with the MS phenotypes has been found previously in blood and CSF. Expression of miR-145 was upregulated while that of miR-660 and miR-939 was downregulated in plasma of MS patients (Søndergaard et al., 2013) . Also, were upregulated in the plasma of RRMS patients compared to healthy controls (HC), and miR-92a-1*, miR-135a, miR-454, miR-500 and miR-574-3p were upregulated in the plasma of RPMS patients compared to SPMS patients (Gandhi et al., 2013) . Furthermore, miR-15b, miR-23a, and miR-223 were downregulated in serum of both RRMS and PPMS, with no differences found between the MS phenotypes (Fenoglio et al., 2013) . MiR-181c and miR-633 were upregulated whereas miR-922 was downregulated in the CSF of MS patients compared to patients with other neurologic diseases, and with miR-181c and miR-633 differentiating RRMS from SPMS patients (Haghikia et al., 2012) . Earlier studies also found associations between the expression of miRNAs and MS disability or disease progression (Gandhi et al., 2013; Huang et al., 2016) .
The steps involved in the review and its contents are shown (Figure 1) . A total of 16 research articles were found. Thirteen of these had measured miRNAs in blood (two had used peripheral blood, one had used peripheral blood leukocytes, seven had used serum, and three had used exosomes isolated from serum) ( Table 1) and three had analyzed miRNAs in CSF ( Table 2) . Ten of the studies utilizing blood had used qPCR to analyze/ validate miRNAs, and all three of the studies with CSF had used qPCR. While most of the studies had used quite large cohorts of MS patients and HC (≥ 30/group), there were a few that had used much smaller cohorts (< 30/group). All of the studies reported on composition of the groups in terms of gender (mainly female) and age, which were similar between MS patients and HC. Diagnosis of MS was based on the 2010 revised McDonald criteria (Polman et al., 2011) . The mean duration of disease from diagnosis ranged from 2.2 to 20.4 years for RRMS, from 8.0 to 20.4 years for SPMS, and from 7.6 to 16.6 years for PPMS. In addition, the mean EDSS scores, which are a measure of ambulatory disabililty, ranged from 0.5 to 6.3 for RRMS, from 4.5 to 6.6 for SPMS, and from 5.1 to 5.9 for PPMS. In some studies none of the MS patients had received disease-modifying treatment (DMT) for a considerable period of time prior to study entry, while in others, patients were receiving treatment at the time of blood sample collection. Administration of DMT medications during the course of the study may constitute a confounding factor. Eleven of the studies had used receiver operating characteristics (ROC) analysis with area under curve (AUC) values to establish which miRNAs are good or fair tests to distinguish MS and its subtypes from HC and to distinguish between the various MS subtypes. The studies were performed in several different countries, although only one study had indicated the race of the participants (Magner et al., 2016) .
The important findings from the research articles in the PubMed searches are summarized as follows: 1) Peripheral blood: A large-scale study by Nuzziello et al. (2018) that included 58 MS patients, comprising 54 RRMS (93%) and 4 SPMS (7%), and 20 HC showed using PCR that miR-320a (fold change, FC = 1.79), miR-125a-5p (FC = 1.89), miR-652-3p (FC = 1.51), miR-185-5p (FC = 1.5), miR-942-5p (FC = 1.67), and miR-25-3p (FC = 1.49) were significantly upregulated in MS compared to HC. The AUC values for the validated miRNAs ranged from 0.701 to 0.735 for miR-320a, miR-185-5p, miR-125a-5p and miR-652-3p, and are fair tests for discriminating MS patients from HC, with miR-320a having the highest AUC value (0.735). In a study by Liguori et al. (2018) involving 19 pediatric MS (PedMS) patients and 20 healthy pediatric controls (PC) and with were significantly upregulated and 1 miRNA (miR-148b-3p) significantly downregulated in PedMS compared to PC. PedMS patients were analyzed during the inactive phase of RRMS disease course, and at the time of blood sample all treated patients were receiving interferon β-1 therapy.
2) Peripheral blood leukocytes: Magner et al. (2016) recovered leukocytes from whole blood samples of 24 MS patients, comprising 19 RRMS (79%) and 5 SPMS (21%), and 20 HC, and by next generation sequencing analysis 13 miRNAs (miR-484, miR-9-5p, miR-323b-3p, miR-15b-5p, miR-145-5p, miR-337-5p, miR-485-5p, miR-654-3p, miR-377-3p, miR-493-5p, miR-301b, miR-409-3p, miR-494) were significantly upregulated and 3 miRNAs (miR-451a, miR-144-5p, miR-101-3p) significantly downregulated in untreated RRMS patients compared to HC. The highest logFC values were for miR-337-5p (logFC = 1.58), miR-144-5p (logFC = -1.98) and miR-451a (logFC = -1.71). Two miRNAs (miR-146b-5p, miR-874) were negatively correlated with EDSS, and two others (miR-107, miR-3614) were positively correlated, in untreated RRMS patients.
3) Blood serum: In a large-scale study by Vistbakka et al. (2018) with 53 RRMS patients, 20 PPMS patients and 27 HC, it was found by RT-PCR that 2 miRNAs were significantly upregulated in both RRMS and PPMS, miR-191-5p (RRMS, FC = 1.65; PPMS, FC = 1.75) and miR-24-3p (RRMS, FC = 2.10; PPMS, FC = 3.58), compared to HC. There were no statistically significant differences between RRMS and PPMS. Active DMT treatment was ongoing in 37 patients with RRMS, (70%) and no significant differences in miRNA expression levels were found between untreated and treated MS patients. Regev et al. (2018) studied miRNA expression in four cohorts of patients: CLIMB cohort comprising 24 RRMS, 18 SPMS, 30 HC; AMIR cohort 31 RRMS, 5 SPMS, 19 HC; EPIC cohort 27 RRMS, 7 SPMS, 26 HC; STORM II cohort 33 RRMS, 21 SPMS, 13 HC. None of the selected patients were receiving DMT at the time of sample collection. By RT-PCR, only the upregulated expression of miR-484 was significantly different when comparing RRMS with HC after accounting for multiple comparisons to control for false discovery rate. Using a combination of miR-15b-5p, miR-451a and miR-584-5p in the reproducibility phase gave AUC 0.676 for discriminating between RRMS and HC. When SPMS and HC were compared, remained significantly different after accounting for multiple group comparisons. A combination of let-7c-5p, miR-320a and miR-424-5p in the reproducibility phase resulted in AUC 0.706 for discriminating SPMS from HC. SPMS patients had significantly decreased miR-337-3p expression compared to RRMS patients in 3 of the 4 cohorts. A combination of miR-134-5p, miR-337-3p and miR-532-3p in the reproducibility phase yielded AUC 0.630 in discriminating RRMS vs. SPMS. In the disability correlation analysis, miR-320a, miR-337-3p, miR-199a-5p, and miR-142-5p correlated with the EDSS in the re- The PedMS patients and PC controls differed significantly for age at study entry, but there was no significant gender difference between them. The investigation performed using a High-Throughput Next Generation Sequencing approach was followed by an integrated bioinformatics/ biostatistics analysis. This revealed 49 mature miRNAs significantly differentially expressed between PedMS and PC. After further selection, the total was reduced to 27 miRNAs that were subjected to qRT-PCR validation. In the validation study, 12 miRNAs (let-7a-5p, let-7b-5p, miR-25-3p, miR-125a-5p, miR-942-5p, miR-221-3p, miR-652-3p, miR-182-5p, miR-185-5p, miR-181a-5p, miR-320a, miR-99b-5p) were significantly upregulated and 1 miRNA (miR-148b-3p) significantly downregulated in PedMS compared to PC.
The interactions between the validated miRNAs and their targets uncovered predicted genes related to immunological functions (i.e., TNFSF13B, TLR2, BACH2, KLF4), as well as genes involved in autophagyrelated processes (i.e., ATG16L1, SORT1, LAMP2) and ATPase activity (i.e., ABCA1, GPX3 Healthy controls had no history of any autoimmune disease or use of any immunomodulatory therapy.
By RT-PCR, miR-24-3p and miR-191-5p were expressed in all the samples, while miR-128-3p and miR-376c-3p were expressed in 95% and 87% of the samples, respectively. Overexpression of miR-128-3p, miR-191-5p, and miR-24-3p occurred in sera of patients with MS (RRMS and PPMS) compared to HC, although after the Bonferroni correction (to reduce type-1 errors, false positives) only miR-191-5p and miR-24-3p remained statistically significant. Expression levels of miR-376c-3p did not differ between the groups. Overexpression was found of miR-191-5p (RRMS, P = 0.01, FC = 1.65; PPMS, P < 0.001, FC = 1.75) and miR-24-3p (RRMS, P = 0.01, FC = 2.10; PPMS, P = 0.01, FC = 3.58) in both subtypes and miR-128-3p in PPMS (P = 0.03, FC = 1.72) compared to HC. After the Bonferroni correction, miR-128-3p did not reach statistical significance. No statistically significant differences were found between RRMS and PPMS. Comparison between untreated and treated MS patients did not show any statistical differences in miRNA expression levels. In the male population, miR-128-3p and miR-191-5p were overexpressed in RRMS (P = 0.007, FC = 11.33 and P = 0.009, FC = 4.68), PPMS (P = 0.023, FC = 3.56 and P = 0.022, FC = 4.01) and among all patients with MS (P = 0.003, FC = 7.49 and P = 0.004, FC = 4.40) compared to HC. Also, miR-128-3p was overexpressed in RRMS compared to PPMS (P = 0.038, FC = 3.18). However, the results of PPMS to HC and PPMS to RRMS comparisons did not pass the Bonferroni correction. In the female population, miR-24-3p was overexpressed in RRMS (P = 0.020, FC = 1.78), PPMS (P = 0.011, FC = 6.06) and in all patients with MS (P = 0.007, FC = 2.62) compared to HC. The RRMS to HC comparison did not pass the Bonferroni correction. Overexpression of miR-24-3p was detected in PPMS cohort in male to female comparison (P = 0.038, FC = 8.17) but it did not pass the Bonferroni correction.
In the whole MS group, miR-24-3p showed positive correlation with the progression index, and after adjustment for gender, disease subtype, and age, this correlation was preserved.
In the RRMS group, miR-128-3p showed positive correlation with ARR, and this became stronger after adjustment for gender and age. In the PPMS group, miR-376c-3p tended to correlate positively with EDSS, but was not preserved after gender and age adjustment.
In MS, serum miR-24-3p and miR-128-3p showed a tendency of association with disability and disease activity, respectively. In the reproducibility phase 73 miRNAs showing promise as biomarkers from a larger validation set of participants from CLIMB patients (validation phase) were further analysed by RT-PCR with MS group (24 RRMS, 18 SPMS) and 30 HC from the CLIMB cohort. Five previously validated miRNAs viz. miR-484, miR-320a, miR-320c, miR-486-5p (all increased) and miR-140-5p (decreased) showed a significant difference, and 1 miRNA remained significant after accounting for multiple comparisons to control for false discovery rate (miR-484) . In a comparison between RRMS and HC, only miR-484 showed a significant difference after accounting for multiple comparisons. When SPMS and HC were compared, 8 miRNAs were significantly different, and 6 miRNAs (mR-484, miR-140-5p, miR-142-5p, miR-320a, miR-320b, miR-320c) were significantly different after accounting for multiple comparisons. When RRMS and SPMS were compared, no previously validated miRNAs were significantly different between the groups. Four miRNAs, miR-320b, miR-337-3p, miR-199a-5p, and miR-142-5p, were significantly correlated with EDSS in the reproducibility phase cohort. In the transportability phase the 73 miRNAs were further analysed in 3 external cohorts with study participants from 3 MS centers worldwide with 91 RRMS, 33 SPMS and 58 HC. For the comparison of MS and HC, 4 miRNAs were differentially expressed in 2 of the 4 MS cohorts: let-7e-5p, let-7f-5p, miR-486-5p, miR-30e-5p. For the comparison of RRMS and HC, 2 miRNAs were differentially expressed in 2 of the 4 MS cohorts: let-7e-5p and let-7f-5p. For the comparison of SPMS and HC, miR-320a, miR-320b, miR-320c and miR-486-5p were differentially expressed in the CLIMB and STORMS II cohorts. The expression of miR-337-3p negatively correlated with EDSS in the discovery set (n = 85) and validation phase (n = 58). These findings were further tested in samples from the reproducibility phase and transportability phase. Results showed that miR-337-3p was negatively correlated with EDSS in 3 of 4 cohorts. An additional 5 miRNAs (miR-142-5p, miR-199a-5p, miR-330-3p, miR-194-5p, miR-941) showed a significant correlation in 2 of the cohorts. In the CLIMB cohort, SPMS patients have significantly decreased miR-337-3p expression compared to RRMS patients. Comparisons between SPMS and RRMS in the other 3 cohorts showed a similar reduction in miR-337-3p expression in SPMS patients compared to RRMS patients in 3 of the 4 cohorts.
Including let-7c-5p, miR-452-5p and miR-484 in a predictive model for MS vs. HC gave by ROC analysis an AUC value of 0.85 in the validation cohort. By qRT-PCR assay, 20 EBV miRNAs were expressed robustly and detectable in all samples. Expression of ebv-miR-BHRF1-2-5p and ebv-miR-BHRF1-3 was significantly increased in RRMS patients compared to HC (FC = 1.48 and 1.33, respectively), while the other 18 miRNAs showed no significant difference. The upregulated expression of ebv-miR-BHRF1-2-5p and ebv-miR-BHRF1-3 was associated positively with EDSS scores of RRMS patients
By ROC analysis, the AUC values for ebv-miR-BHRF1-2-5p and ebv-miR-BHRF1-3 used independently were 0.74 and 0.72, respectively. With a combination of the two miRNAs, the AUC value was 0.76. Among the candidate target genes of ebv-miR-BHRF1-2-5p and ebv-miR-BHRF1-3, mucosaassociated lymphoid tissue lymphoma transport protein 1 (MALT1) was predicted to have two potential binding sites for ebv-miR-BHRF1-2-5p on the 3′-UTR. MALT1 is involved in immune homeostasis (Gewies et al., 2014; Jaworski et al., 2014) . Also a binding site for ebv-miR-BHRF1-3 was found within the mRNA of phosphatase and tensin homologue (PTEN), which had been confirmed previously as a target of ebv-miR-BHRF1-3 (Bernhardt et al., 2016) . Expression of miRNAs was measured using RT-PCR. Of the 84 miRNAs analysed in the screening phase, 4 were significantly downregulated (miR-375, miR-130b-3p, miR-141-3p, miR-124-3p) and 5 were upregulated (miR-128-3p, miR-376c-3p, miR-191-5p, miR-26a-5p, miR-24-3p) in PPMS compared to HC. In the validation phase, when the group including all MS patients was compared to HC, 5 miRNAs (miR-128-3p, miR-376c-3p, miR-26a-5p, miR-191-5p, miR-24-3p) were upregulated (FC > 1.5, P < 0.05), but after the Bonferoni correction (to reduce the chances of obtaining false-positive results) only the differences for 4 miRNAs (miR-128-3p, miR-376c-3p, miR-26a-5p, miR-191-5p) reached statistical significance. Of these, miR-191-5p had the strongest upregulation in PPMS (FC = 1.9). Analysis between the groups revealed significant upregulation of 5 miRNAs (miR-128-3p, miR-376c-3p, miR-26a-5p, miR-191-5p, miR-24-3p) in PPMS compared to HC. After the Bonferroni correction, 4 of them (miR-128-3p, miR-376c-3p, MIR-191-5p, miR-24-3p) remained statistically significant. miR-191-5p showed the greatest upregulation (FC = 2.3). In SPMS, 3 miRNAs (miR-376c-3p, miR-26a-5p, miR-191-5p) were upregulated (FC > 1.5, P < 0.05), but only miR-191-5p remained statistically significant after the Bonferroni correction (FC = 1.6). Comparison between PPMS and SPMS showed that 2 miRNAs (miR-128-3p, miR-24-3p) were significantly upregulated in PPMS after the Bonferroni correction (miR-128-3p, FC = 1.5; miR-24-3p, FC = 1.5). In the screening and validation phases, 18 MS and 9 HC samples were the same. To confirm that the results could be replicated in an independent cohort, additional logistic regression model analyses were performed excluding all the overlapping samples. Analysis showed that 3 miRNAs (miR-128-3p, miR-26a-5p, miR-191-5p) were significantly expressed in progressive MS patients (PPMS and SPMS) compared to HC as was detected in the whole validation cohort. The expression of miR-376c-3p did not differ statistically between MS and HC. Comparison between the groups showed that 3 miRNAs (miR-128-3p, miR-26a-5p, miR-191-5p) were significantly expressed in PPMS and 2 miRNAs (miR-26a-5p, miR-191-5p) in SPMS compared to HC. No differences in the expression levels were detected between PPMS and SPMS. However, the independent cohort was of very small size (n = 13) for PPMS vs. HC and for PPMS vs. SPMS. In PPMS vs. HC, expression of miR-376-3p was on border of statistical significance (P = 0.07) and for PPMS vs. SPMS, expression of miR-128-3p was on border of statistical significance (P = 0.07). In the whole MS group, expression of miR-124-3p correlated positively with time from first symptoms. The SPMS group had a positive correlation between expression of miR-128-3p and progression index. In the PPMS group, miR-124-3p correlated with time from first symptoms and miR-375 with age. When patients with EDSS > 6 were excluded from the analysis, a negative correlation was found between miR-375 and progression index in PPMS. MiRNAs were measured by RT-qPCR. In cohort 1, the miRNAs that demonstrated strong correlations with MRI were similar for brain parenchymal fraction and global cerebral GM fraction. However, the miRNAs associated with lesions were mostly different from those associated with atrophy, suggesting different pathogenic processes underlying focal lesions (inflammatory demyelination) vs. neurodegeneration (axonal and neuronal loss). In cohort 2, miRNAs that showed a strong correlation with wholebrain atrophy also indicated a strong correlation with cerebral GM atrophy. However, a different set of miRNAs correlated with spinal cord vs. brain atrophy. Although several mRNAs were associated with MRI outcome, none of these associations remained significant when correcting for multiple comparisons using false discovery rate. Several miRNAs showed significant associations with EDSS score in both cohorts. These associations for seven miRNAs miR-19a-3p, miR-101-3p, miR-30e-3p, miR-19b-3p, miR-29c-3p, miR-32-5p, miR-195-5p remained significant after correcting for multiple comparisons using false discovery rate. All of these miRNAs except for miR-195-5p had a protective relationship shown by a higher miRNA expression being associated with lower severity of MRI-indicated involvement. MiR-195-5p had a pathogenic relationship shown by a higher miRNA expression being associated with greater severity of MRI-indicated involvement. By RT-PCR, in the discovery phase 167 miRNAs were identified that were differentially expressed between patients with MS and HC. After filtering using the selection criteria, 40 miRNAs were chosen for further validation.
Significant
In the validation phase, 7 miRNAs were significantly differentially expressed in MS compared to HC. Of these 7 miRNAs, 6 were significantly different after correcting for multiple comparisons using false discovery rate: miR-320a, miR-486-5p, miR-320b, miR-25-3p, miR-140-3p (all upregulated) and let-7c-5p (downregulated). The findings remained unchanged after adjustment for age and gender.
By ROC analysis, the highest AUC value was for miR-320a (0.707) and discriminated MS patients from HC. When all 6 miRNAs that were significant after correcting for multiple comparisons were combined (miR-320a + miR-486-5p + miR-320b + miR-25-3p + miR-140-3p + let-7c-5p) the AUC value was 0.795. To identify disease category biomarkers, in the discovery phase 21 miRNAs were identified that were differentially expressed between the groups. In the validation phase, miR-27a-3p and miR-376-3p were significantly differentially expressed in RRMS compared to SPMS in the same direction in the discovery and validation phases. MiR-27a-3p had the highest AUC value (0.78) and only this miRNA remained significant after correcting for multiple comparisons. The results were the same after adjustment for age and gender. In the comparison of RRMS to PPMS, none of the miRNAs selected from the discovery phase were validated in the validation phase. To investigate the association between miRNAs and disability, in the discovery phase using all untreated patients with MS (plus 59 additional patients with RRMS), 103 miRNAs were significantly associated with EDSS score, and 40 were selected for further validation. In the validation phase, 10 miRNAs were significantly associated with EDSS score, and 9 remained significantly correlated to EDSS after adjusting for age. Two of these miRNAs miR-199a-5p, and miR-142-5p remained significantly correlated to EDSS after correcting for multiple comparisons. The highest correlation with EDSS was with miR-199a-5p. (Peterson M et al., 2015) . The vesicles isolated from sera were confirmed to be exosomes based on size (30-100 nm) as determined by nanoparticle tracking analysis (NTA) and expression of exosomal protein markers CD9 and Alix. There were no significant differences in total number of exosomes in sera of RRMS patients in relapse and in remission or HC. There were no significant differences in total amount of exosome RNA in sera of RRMS patients in relapse or remission and HC RNA isolation from the exosomes was performed. Analysis by qPCR showed a decreased expression of miR-155 and miR-301a (in 94% and 51% samples, respectively) and an increased expression of miR-326 (in 72% samples) in RRMS patients (n = 36). The difference in relative expression of miR-155 for RRMS patients compared to HC was statistically significant. No correlation was found between expression levels of miR-155, miR-326 and miR-301a and age. A positive correlation was found between relative expression of miR-326 and miR-301a and BDI. A positive correlation was found between RQ (relative quantification) miR-301a and MoCA. Expression levels of miR-301a and miR-155 were higher in RRMS patients in postacute vs. stable phase of remission. Statistically significant differences in RQ values between early vs. late phase of remission were found for miR-301a and miR-155. There was no significant difference in the case of miR-326. Statistical analysis between two groups of RRMS patients with BDI ≤ 11 vs. BDI > 11 revealed lower miR-326 and miR-301a expression levels in patients with BDI ≤ 11, while miR-155 expression was increased in BDI ≤ 11. A statistically significant difference was found for miR-326, but not for miR-301a and miR-155. Statistical analysis between HC, RRMS BDI > 11 and RRMS BDI ≤ 11 showed significant differences only for miR-326, with a significantly higher expression in RRMS BDI > 11 vs. HC. On dividing RRMS patients into two subgroups based on their disability EDSS ≤ 5 and EDSS > 5, no significant differences were found in expression level of miR-155, miR-326 and miR-301a. Using NGS and three statistical approaches, 4 significantly upregulated miRNAs were identified for RRMS patients compared to HC (miR-15b-5p, miR-30b-5p, miR-342-3p, miR-451a), and 4 significantly upregulated miRNAs for SPMS/PPMS patients compared to ). There were 3 significantly upregulated miRNAs for RRMS compared to SPMS/PPMS patients. MiRNAs were identified as differentially expressed if they met a fold-change ≥ 2 and P ≤ 0.05 in at least two of the three statistical tests. In the validation study, 6 miRNAs were significantly upregulated in SPMS/PPMS patients compared to ). In addition, 9 miRNAs were dysregulated in RRMS compared to SPMS/ PPMS patients (miR-15b-5p, miR-23a-3p, miR-223-3p, miR-30b-5p, miR-342-3p, miR-374a-5p all upregulated, and miR-432-5p, miR-433-3p, miR-485-3p all downregulated (P < 0.05 in at least two tests and FC ≥ 1.7 in either direction)). In the comparison of MS patients and OND controls, no differences were found for gender distribution or age in discovery cohort or in validation cohort. Similarly when separated into MS LS_OCMB-, MS LS_OCMB+, OND, no differences were found for gender distribution or age. Clinical and radiological data collected for MS patients from MRI performed within a mean of 3 months did not show any differences between LS_OCMB-and LS_OCMB+, except for onset symptoms where 50% of LS_OCMB+ patients presented medullar symptoms. In the discoverv study using RT-PCR, 62 miRNAs were detected in at least 75% of individuals. Of these miRNAs, 12 had significantly different expression for and . Greatest fold change values for upregulated miRNAs were for miR-30a-5p FC = 8.0 and miR-520c-3p FC = 6.4, while for downregulated miRNAs were for miR-140 FC = -3.8 and miR-19a FC = -3.4. In the validation study using RT-PCR, statistically significant differences in expression for MS vs. OND control were found for miR-328, miR-30a-5p, miR-150, miR-645 (upregulated in MS) and . Four miRNAs showed significantly different expression in LS_OCMB+ vs. OND controls: miR-30a-5p, miR-150, miR-645 (upregulated in LS_OCMB+) and miR-191 (downregulated in LS_OCMB+). Two miRNAs had significantly different expression in LS_ OCMB-vs. OND controls: miR-199a-3p and miR-106a (downregulated in LS_OCMB-). No significant differences were found for any miRNA between LS_OCMB+ and LS_OCMB-. By qRT-PCR, 15 miRNAs were selected from the analysis of pooled CIS, MS, NINDC and INDC cell-free CSF samples for examination in validation cohort 1. Of the tested miRNAs, only miR-145 and miR-150 were significantly different for MS compared to NINDC control. In the larger validation cohort 2, it was possible to replicate significantly higher levels of miR-150 in MS compared to both NINDC and INDC controls as well as being significantly higher between CIS and NINDC. Also a significantly higher level of miR-145 in MS compared to NINDC was found. Significantly higher miR-150 levels were found in CSF from patients with CIS who subsequently converted to MS compared to those who did not convert during follow-up (median period of 52 months). High levels of miR-150 correlated with higher CSF cell numbers and higher IgG index, indicating that miR-150 associated with active inflammation. In contrast, miR-150 levels did not correlate with the number of MRI T2 lesions and EDSS score, and there was only a tendency for higher miR-150 levels in relapse. g, 10 minutes) . The cellfree supernatants of CSF and serum were stored frozen until the measurement of miRNAs. A dysfunction of the blood-CSF barrier was defined by CSF/serum albumin quotient (Qalb) higher than age-adjusted upper reference limit calculated as 4 + (age in years)/15 (Reiber, 1998) .
By qRT-PCR, levels of miR-922 in CSF and serum were significantly higher in CIS-RRMS than CIS-CIS patients. While miR-181c levels in CSF were significantly higher in CIS-RRMS than CIS-CIS patients, there was no difference in serum levels of miR-181c between the two groups. No differences were found between CIS-CIS RRMS and CIS-CIS patients for miR-633 in both CSF and serum. Levels of the investigated miRNAs did not significantly correlate with age, EDSS, CSF cell count, total protein levels in CSF and Qalb. In univariate Cox regression analyses, lower levels of CSF miR-181c and serum miR-922 were significantly associated with a lower risk of conversion from CIS to RRMS. None of the other miRNAs were significantly associated with conversion to RRMS. Of the other baseline factors, younger age, and > 9 lesions on MRI, were significantly associated with conversion to RRMS. In the multivariate Cox regression analyses, CSF miR-181c, age, and MRI were significantly associated with conversion from CIS to RRMS, while serum miR-922 was not significantly associated with conversion to RRMS.
By ROC analysis, for CSF miR-181c the AUC value was 0.67. Combining MRI, age and CSF miR-181c resulted in an increased AUC value of 0.83 and improved values of specificity and positive predicted value for conversion to RRMS compared to CSF miR-181c alone or the combination of age and MRI (96% and 94%, respectively) CSF miR-181c might serve as a biomarker for early conversion to RRMS. producibility phase cohort. In a previous study Vistbakka et al. (2017) studied miRNA expression in a validation phase with 31 PPMS patients, 31 SPMS patients, 21 HC and found using RT-PCR when the group including all MS patients was compared to HC, 5 miRNAs (miR-128-3p, miR-376c-3p, miR-26a-5p, miR-191-5p, miR-24-3p) were significantly upregulated (FC > 1.5), but after the Bonferroni correction (to reduce the chances of obtaining false-positive results) only the differences for 4 miRNAs (miR-128-3p, miR-376c-3p, miR-26a-5p, miR-191-5p) reached statistical significance. 5 miRNAs were significantly upregulated (miR-128-3p, miR-376c-3p, miR-26a-5p, miR-191-5p, miR-24-3p) in PPMS compared to HC, and after the Bonferroni correction, 4 of them (miR-128-3p, miR-376c-3p, miR-191-5p, miR-24-3p) remained statistically significant, with miR-191-5p showing the greatest upregulation (FC = 2.3). In SPMS, 3 miR-NAs (miR-376c-3p, miR-26a-5p, miR-191-5p) were upregulated (FC > 1.5) compared to HC, but only miR-191-5p (FC = 1.6) remained statistically significant after the Bonferroni correction. Comparison between PPMS and SPMS showed that 2 miRNAs (miR-128-3p, miR-24-3p) were significantly upregulated in PPMS after the Bonferroni correction (miR-128-3p, FC = 1.5; miR-24-3p, FC = 1.5 -145, miR-223, miR-326, SP1, and SMAD3. Regev et al. (2017) studied two cohorts of patients: cohort 1 comprised 29 RRMS, 7 SPMS, 5 PPMS, while cohort 2 comprised 66 RRMS, 10 SPMS, 3 PPMS, with levels of miRNAs measured by RT-PCR being examined in relation to findings of MRI scans to identify brain lesions, brain atrophy, and cervical spinal cord lesions and atrophy. Many of the patients received DMT at MRI especially in cohort 2. Although several miRNAs were associated with MRI outcome, none of these associations remained significant when correcting for multiple comparisons using false discovery rate. Several miRNAs showed significant associations with EDSS score in both cohorts. These associations for 7 miRNAs (miR-19a-3p, miR-101-3p, miR-30e-3p, miR-19b-3p, miR-29c-3p, miR-32-5p, miR-195-5p ) remained significant after correcting for multiple comparisons using false discovery rate. All of these miRNAs except for miR-195-5p had a protective relationship shown by a higher miRNA expression being associated with lower severity of MRI-indicated involvement. MiR-195-5p had a pathogenic relationship shown by a higher miRNA expression being associated with greater severity of MRI-indicated involvement. In addition, Regev et al. (2016) studied 29 RRMS, 19 SPMS, 10 PPMS, 30 HC in a validation phase and by RT-PCR identified 6 miRNAs differentially expressed in MS compared to HC after correcting for multiple comparisons using false discovery rate: miR-320a, miR-486-5p, miR-320b, miR-25-3p, miR-140-3p (all upregulated) and let-7c-5p (downregulated). The findings remained unchanged after adjustment for age and gender. By ROC analysis, miR-320a had the highest AUC 0.707 for discriminating MS from HC. When all 6 miRNAs that were significant after correcting for multiple comparisons were combined, the AUC value increased to 0.795 for MS vs. HC. MiR-27a-3p and miR-376-3p were significantly upregulated in RRMS compared to SPMS. MiR-27a-3p had the highest AUC value (0.78) and only this miRNA remained significant after correcting for multiple comparisons. The results were the same after adjusting for age and gender. Also miR-199a-5p, and miR-142-5p were significantly correlated to EDSS score after correcting for multiple comparisons. The highest correlation to EDSS was with miR-199a-5p. In this study, patients had not received treatment in the past 1 month, 3 months or 6 months depending on the treatment. In a study of Epstein-Barr virus (EBV) associated with MS, Wang et al. (2017) examined the expression of EBV miRNAs using RT-PCR in 30 RRMS patients at relapse and 30 HC who had not received treatment within the previous 2 months. 20 EBV miRNAs were expressed in all samples, and expression of ebv-miR-BHRF1-2-5p and ebv-miR-BHRF1-3 was significantly increased in RRMS patients compared to HC (FC = 1.48 and 1.33, respectively), while the other 18 miRNAs showed no significant difference. The upregulated expression of ebv-miR-BHRF1-2-5p and ebv-miR-BHRF1-3 was associated positively with EDSS scores of RRMS patients. By ROC analysis, the AUC values for ebv-miR-BHRF1-2-5p and ebv-miR-BHRF1-3 for discriminating RRMS from HC were 0.74 and 0.72, respectively, while with a combination of the two miRNAs, the AUC value was 0.76. 4) Exosomes isolated from serum: Selmaj et al. (2017) recruited 33 RRMS relapse, 30 RRMS remission and 32 HC in a validation set. All patients were sampled before methylprednisolone administration, and those in remission did not receive DMT for at least 6 months. By PCR, were significantly downregulated in RRMS relapse patients compared to HC, while miR-122-5p was significantly downregulated in RRMS remission patients compared to HC. Furthermore, were significantly downregulated in RRMS relapse patients compared to RRMS remission patients. By ROC analysis, , AUC values were 0.878, 0.866, 0.681, 0.800, respectively, for discriminating between RRMS patients in relapse and HC. A combination of miR-122-5p and miR-196b-5p gave AUC 0.904 for discriminating RRMS relapse from HC and AUC 0.866 for distinguishing RRMS relapse from RRMS remission. Lower levels of miR-122-5p, miR-196b-5p, miR-301a-3p, miR-532-5p were related to disease activity. Niwald et al. (2017) studied 23 stable RRMS, 13 post-acute RRMS patients and 10 HC. The stable RRMS patients were in the remission phase, without treatment, for over 2 years without attacks or steroid treatment (late phase of remission). The post-acute RRMS patients were in the early phase of remission, 1 to 2 months free of intravenous injection of 5-day methyl-prednisolone (1000 mg/d). Using PCR, expression of miR-155 and miR-301a was decreased (in 94% and 51% samples, respectively) whereas expression of miR-326 was increased (in 72% samples) in RRMS patients. The difference in relative expression of miR-155 for RRMS patients compared to HC was statistically significant. Expression levels of miR-301a and miR-155 were higher in RRMS patients in post-acute vs. stable phase of remission. Significant differences in relative quantitation values between early vs. late phase of remission were found for miR-301a and miR-155. There was no significant difference in the expression level of miR-326. A positive correlation was found between relative expression of miR-326 and miR-301a and Beck Depression Index. On dividing RRMS patients into two subgroups based on their disability EDSS ≤ 5 and EDSS > 5, no significant differences were found in miR-155, miR-326 and miR-301a level of expression. Ebrahimkhani et al. (2017) using next generation sequencing in a validation study with 14 RRMS, 11 SPMS7/PPMS4 and 11 HC identified 4 significantly upregulated miRNAs for RRMS patients compared to . Also, 6 miRNAs were significantly upregulated in SPMS/PPMS patients compared to ). Furthermore, 9 miRNAs were dysregulated in RRMS compared to SPMS/PPMS patients (miR-15b-5p, miR-23a-3p, miR-223-3p, miR-30b-5p, miR-342-3p, miR-374a-5p all upregulated, and miR-432-5p, miR-433-3p, miR-485-5p all downregulated . Four miR-NAs showed significantly different expression in LS_OCMB+ vs. OND: miR-30a-5p, miR-150, miR-645 (upregulated in LS_ OCMB+) and miR-191 (downregulated in LS_OCMB+). Two miRNAs had significantly different expression in LS_OCMBvs. OND: miR-199a-3p and miR-106a (downregulated in LS_ OCMB-). There were no significant differences for any miRNA between LS_OCMB+ and LS_OCMB-. By ROC analysis, miR-150 had the highest AUC value (0.684) for distinguishing MS patients from OND. Bergman et al. (2016) recruited two validation cohorts of patients: cohort 1 comprised 34 CIS, 43 MS, 34 noninflammatory neurologic disease controls (NINDC), 31 inflammatory neurologic disease controls (INDC), while cohort 2 constituted 96 CIS, 120 MS, 119 NINDC, 95 INDC. By RT-PCR, only miR-145 and miR-150 of the tested miRNAs were significantly different for MS compared to NINDC control in cohort 1. In the larger validation cohort 2, significantly higher levels of miR-150 in MS compared to both NINDC and INDC controls were replicated, as well as being significantly higher between CIS and NINDC. In addition, a significantly higher level of miR-145 for MS compared to NINDC was observed. Significantly higher miR-150 levels were found in CSF from CIS patients who subsequently converted to MS compared to those who did not convert during follow-up (median period of 52 months). By ROC analysis, miR-150 level discriminated MS patients in relapse/remission from NINDC controls with AUC value 0.744 (sensitivity 0.890, specificity 0.500). The ratio of miR-150 to miR-204 was significantly higher in MS compared to NINDC and INDC in cohort 2, as well as in patients with CIS who subsequently converted to MS compared to those who did not convert. The ratio of miR-150 to miR-204 had an AUC value of 0.811 (sensitivity 0.710, specificity 0.790) for differentiating MS from NINDC, and also an AUC value of 0.775 for differentiating patients with CIS who converted to MS from those who did not convert. Similar to the pair miR-150/miR-204, the pair miR-145/miR-204 also distinguished MS from NINDC. Ahlbrecht et al. (2016) recruited 28 CIS-CIS and 30 CIS-RRMS patients. CIS patients had a CIS disease status 1 year after CIS diagnosis or converted to RRMS within 1 year. A considerable proportion of CIS-CIS (36%) and CIS-RRMS (37%) patients received DMT. By RT-PCR, levels of miR-922 in CSF and serum were significantly higher in CIS-RRMS than CIS-CIS patients. While miR-181c levels in CSF were significantly higher in CIS-RRMS than CIS-CIS patients, there was no difference in serum levels of miR-181c between the two groups. No differences were found between CIS-CIS RRMS and CIS-CIS patients for miR-633 in both CSF and serum. In univariate Cox regression analyses, lower levels of CSF miR-181c and serum miR-922 were significantly associated with a lower risk of conversion from CIS to RRMS; none of the other miRNAs were significantly associated with conversion to RRMS. By ROC analysis, the AUC value of CSF miR-181c for distinguishing between CIS-CIS and CIS-RRMS patients was 0.67.
AUC
Those miRNAs that can be considered as biomarkers of MS and its subtypes in peripheral blood, blood serum, exosomes isolated from serum, and CSF are summarized ( Table 3 ).
Discussion
MS is a chronic inflammatory demyelinating and neurodegenerative disease of the CNS. Genetic, epigenetic, and environmental factors are likely involved in its susceptibility and/or outcomes (Oksenberg and Baranzini, 2010) . The disease onset typically occurs in young adults, especially females, although diagnosis during childhood and adolescence has been increasingly reported worldwide. In RRMS, inflammation together with blood-brain barrier damage is the key mechanism in the initiation of the disease process. In SPMS and PPMS, inflammation-promoting effects become decreased over time while neurodegenerative events are increased by mechanisms such as oxidative stress and mitochondrial damage, followed by intracellular influx of Na + and Ca 2+ leading to cell death. Widespread diffuse inflammation with slowly expanding lesions and abundant cortical lesions, as well as lymphocyte infiltration and microglia activation in the normal-appearing white matter, is characteristic of the pathology of progressive phenotypes (Vistbakka et al., 2017) .
MiRNAs are involved in neurogenesis, oligodendrocyte differentiation, neurite outgrowth, and myelin formation (Dugas et al., 2010; de Faria et al., 2012; Zhao et al., 2010) . Alterations in miRNA expression have been reported in various pathologies (Esteller, 2011) , particularly those associated with inflammation and immune function (O'Connell et al., 2012; Singh et al., 2013) . In addition, abnormal expression of several components of the miRNA production pathway has been found in various diseases (Divekar et al., 2011; Gascon and Gao, 2012) . Overexpression of Dicer mRNA in peripheral blood leukocytes was shown in MS (Jafari et al., 2015) . Also decreased Dicer protein in B cells from MS patients has been observed (Aung and Balashov, 2015) . Dicer expression is required for normal development of oligodendrocytes (Shin et al., 2009) . Protecting oligodendrocytes from further injury and promoting remyelination may be a feasible way of improving clinical outcome in MS patients in the near future (Rodgers et al., 2013; Dulamea, 2017) .
Previous studies had constructed molecular networks by integrating dysregulated miRNAs and miRNA targets from target gene prediction databases (Angerstein et al., 2012; Hecker et al., 2013; Jernås et al., 2013) . Most were performed using small patient cohort sizes without technical replicates and independent validation (Kemppinen et al., 2011) . Thus, it is possible that some of the findings are false positives. In addition, these studies were conducted using different samples or tissues (e.g., peripheral blood or isolated cells), different technological microarray platforms, and different statistical methods to analyze the data. Consequently, little overlap in expression of dysregulated miRNAs was observed between the various studies (Kemppinen et al., 2011) .
The recent studies reviewed here have shown that miRNAs in blood, especially in blood serum and exosomes isolated from serum ( Table 1 ) and in CSF ( Table 2 ) can serve to distinguish MS patients from controls. In addition, miRNAs in CSF are altered in CIS patients compared to controls and distinguish CIS patients who subsequently convert to MS from those that do not convert ( Table 2 ). The expression levels of a large number of miRNAs have been found to be altered in MS and its subtypes (RRMS, SPMS, PPMS) compared to HC and other neurologic diseases and also in CIS compared to controls (Table 3) , and by ROC AUC analysis have been shown to distinguish the disease subtypes from HC and each other. Thus, these miRNAs have the potential to serve as diagnostic markers for the disease and to distinguish between its subtypes. Apart from two studies that had employed next generation sequencing, all of the studies reviewed had used PCR to validate the findings from discovery or screening sets. In addition, there were indications of overlap in the results from the different research groups and this included miRNAs such as miR-320a and miR-25-3p (upregulated in peripheral blood and blood serum of MS patients vs. HC), miR-191-5p and miR-145 (upregulated in blood serum and CSF of MS patients vs. controls), miR-223 (upregulated in blood serum and exosomes of SPMS patients vs. controls). While MS patients in several studies had received DMT therapy, no statistically significant differences in miRNA expression levels were found between untreated and treated patients in two of the studies (Sharaf-Eldin et al. 2017; Vistbakka et al. 2018) . Clearly the use of similar analytical procedures by the various research groups for detecting and quantifying miRNAs levels has assisted in increasing the levels of similarity between findings. However, while there was agreement with some findings on miRNA expression in previous studies including upregulation of miR-145 in plasma of MS patients (Søndergaard et al., 2013) and serum of MS patients (Sharaf-Eldin et al., 2017) , there were also some differences. For example, a downregulation of miR-15b, miR-23a and miR-223 in serum of both RRMS and PPMS was reported in a previous study (Fenoglio et al., 2013) , whereas an upregulation of miR-15b-5p was found in exosomes from serum for RRMS and SPMS/PPMS and of miR-23a-3p in exosomes from serum for SPMS/PPMS (Ebrahimkhani et al., 2017) and an upregulation of miR-223 in serum of RRMS and SPMS was observed (Sharaf-Eldin et al., 2017) . This lack of agreement could possibly be due to differences in selection/recruitment of patients and possibly being at different stages of MS (relapse vs. remission, early vs. late phase of remission), technologies, analytical procedures, and/or statistical methods, of which the latter in the recent studies were very rigorous and often involved several statistical tests and Bonferroni corrections for false positives. Exosomal miRNA analysis has been considered to provide a more robust and different data set than an analysis of serum miRNAs (Backes et al., 2016; Selmaj et al., 2017) . Gallo et al. (2012) reported that the majority of miRNAs detectable in serum were concentrated in exosomes, and with the concentration of miRNA in whole, unfractionated serum being between that of the exosomal pellet and the exosome-depleted serum supernatant.
Several of the serum miRNAs had high FC values, for example miR-24-3p (FC = 3.58, 2.10), miR-326 (FC = 3.1), miR-191-5p (FC = 2.3). These help to indicate those miRNAs that can serve as markers and provide a quantitative aspect to the results that are more often expressed only qualitatively as increased or decreased expression. Regarding the functionality of these miR-NAs, miR-24 appears to promote pro-apoptotic effects (Zhou and Zhang, 2014) and inhibits interferon-γ (Fayyad-Kazan et al., 2014) and interleukin (IL)-4 expressions (Pua et al., 2016) suggesting a role in the regulation of Th1/Th2 cell balance, thereby regulating inflammatory responses. MiR-326 promotes the differentiation of Th17 cells, which are IL-17 producing T helper CD4 + cells, by targeting Ets-1, a negative regulator of Th17 differentiation. In MS patients, miR-326 was positively correlated with IL-17 production, and this might be associated with chronic autoimmune diseases (Tzartos et al., 2008; Du et al., 2009) . During the course of MS, miR-326-mediated downregulation of CD47 mRNA results in reduced interaction of CD47 with the signal regulatory protein alpha, thus promoting phagocytosis of myelin by macrophages (Koning et al., 2007; Junker et al., 2009 ). MiR-191 regulates cytokine-dependent naïve, memory, and regulatory T cell survival and thereby maintains immune homeostasis by controlling levels of insulin receptor substrate 1 (Lykken and Li, 2016) . Interestingly, miR-326 had increased expression in exosomes isolated from serum of RRMS patients, and was reported to be increased in MS brains (Junker et al., 2009) . A reduction of symptoms occurred in experimental autoimmune encephalomyelitis, a model system for MS, in mice lacking miR-326 by in vivo silencing (Junker, 2011) . Also downregulation of miR-326 by its specific inhibitor (lentivirus-sponge) led to an improved experimental autoimmune encephalomyelitis score through inhibition of Th17 differentiation (Du et al., 2009) .
Expression of miRNAs is controlled by genetic and epigenetic mechanisms. MiRNAs can be epigenetically regulated by DNA methylation and/or specific histone modifications (Moutinho and Esteller, 2017) . Moreover, epigentic mechanisms regulate the human leukocyte antigen-DRB1*15 allele, which is linked to MS disease and possibly one of the reasons why MS is more often transmitted to offspring by mothers than fathers (Küçükali et al., 2015) . Vitamin D deficiency, smoking and EBV are major environmental factors for MS and are all known to exert epigenetic changes. Epigenetic mechanisms could regulate axonal loss, apoptosis, and mitochondrial dysfunction in MS (Küçükali et al., 2015) .
Further studies are warranted by other research groups to independently validate the findings in this review so that single miRNAs or pairs of miRNAs in blood serum and CSF can be used as diagnostic markers for adult onset and PedMS and for monitoring disease progression and response to therapy. Also the functionality of those miRNAs that best discriminate MS and its subtypes from controls needs to be investigated. Table 3 Alterations of miRNA expression in MS and its subtypes in peripheral blood, blood serum, exosomes isolated from serum, and CSF
